<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03948022</url>
  </required_header>
  <id_info>
    <org_study_id>centrumtupbebek</org_study_id>
    <nct_id>NCT03948022</nct_id>
  </id_info>
  <brief_title>Luteal Support in Frozen-Thawed Embryo Transfer Cycles</brief_title>
  <official_title>Which Luteal Support in Frozen-Thawed Embryo Transfer Cycles: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centrum Clinic IVF Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centrum Clinic IVF Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the clinical efficacy of 3 different luteal phase support in patients&#xD;
      undergoing frozen-thawed embryo transfer cycles. Endometrium preparation will be hormone&#xD;
      replacement in all cycles. Starting from day 11, group 1 will receive 100 mg micronized&#xD;
      progesterone parenteral daily injections, group 2 will receive 90 mg bioadhesive gel vaginal&#xD;
      twice daily and group 3 will receive 40 mg oral dydrogesterone daily tablets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In natural pregnancy, successful implantation and pregnancy necessitates well-functioning&#xD;
      corpus luteum. Luteal phase support (LPS) is critical in assisted conception cycles&#xD;
      particularly for replacement frozen embryo transfer cycles owing to lack of corpus luteum. 3&#xD;
      different LPS options have been suggested:&#xD;
&#xD;
        -  Progesterone in oil (intramuscular injections) is rapidly absorbed after i.m. injection&#xD;
           and high progesterone plasma concentrations are reached after approximately 2h. Despite&#xD;
           satisfactory plasma levels, the possible side-effects of pain and swelling are limiting&#xD;
           the use.&#xD;
&#xD;
        -  Vaginal application of progesterone is widely accepted with satisfactory endometrial&#xD;
           levels and patient convenience. However, increased vaginal discharge and possible&#xD;
           vaginal irritation are the most common side effects.&#xD;
&#xD;
        -  Oral administration of synthetic progesterone (dydrogesterone) would offer a convenient&#xD;
           way of progesterone administration. Better bioavailability than natural progesterone and&#xD;
           less cost makes dydrogesterone preferable. Also, good quality evidence revealed&#xD;
           satisfactory outcomes in fresh embryo transfer cycles. However, there is lack of good&#xD;
           quality evidence for dydrogesterone as a LPS in frozen-thawed cycles.&#xD;
&#xD;
      The investigator's aim is to compare 3 widely used LPS in frozen-thawed embryo transfer&#xD;
      cycles.&#xD;
&#xD;
      Following allocation of the subjects, hormone replacement will be scheduled for the&#xD;
      endometrial preparation. Briefly; On day 2 of menstrual bleeding, endometrial preparation&#xD;
      with oral estradiol (E2) (2 mg twice daily) will be initiated. Approximately 10 days after&#xD;
      initiation of E2 administration, the subject will undergo a transvaginal ultrasound&#xD;
      examination to assess endometrial development and serum progesterone (P) level will be&#xD;
      checked. Once the subject achieved a trilaminar endometrium with a thickness of &gt;7 mm with&#xD;
      serum P levels &lt;1.5 ng/ml, she will start the progesterone treatment to which she will be&#xD;
      randomized to one of the 3 arms. After 3 days of P treatment along with E2 pills, cleavage&#xD;
      embryo transfer will be performed. If the subject will receive blastocyst, 5 days of P&#xD;
      treatment will be scheduled.&#xD;
&#xD;
      If these criteria were not met at the first evaluation, she will allowed up to 10 additional&#xD;
      days (20 days total) of estrogen stimulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>12th week of pregnancy</time_frame>
    <description>fetal cardiac activity beyond 12th week of gestation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>6th week of pregnancy</time_frame>
    <description>fetal cardiac activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abortion rate</measure>
    <time_frame>during first 10 weeks of gestation</time_frame>
    <description>miscarriage of the pregnancy pregnancy recently confirmed with positive beta hCG blood test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Implantation; Placenta</condition>
  <condition>Pregnancy Loss</condition>
  <arm_group>
    <arm_group_label>intramuscular progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>progestan (progesterone) 50 mg/ml ampoules, 2 ampoules (100 mg) intramuscular starting from day 11 of the endometrial preparation cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaginal progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>crinone %8 bioadhesive gel (progesterone) 90 mg, twice daily (180 mg/day) starting from day 11 of the endometrial preparation cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral dydrogesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dydrogesterone (progesterone) 10 mg tablets, 2x2 (40 mg total)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone 10Mg Tablet (duphaston)</intervention_name>
    <description>40 mg daily oral tablets</description>
    <arm_group_label>oral dydrogesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone 50Mg/mL Oil</intervention_name>
    <description>100 mg daily intramuscular injections</description>
    <arm_group_label>intramuscular progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crinone 8% Vaginal Gel</intervention_name>
    <description>180 mg daily vaginal gels</description>
    <arm_group_label>vaginal progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  woman aged 20-40 years&#xD;
&#xD;
          -  Having available blastocyst(s) cryopreserved by vitrification method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  requirement for fresh embryo(s);&#xD;
&#xD;
          -  presence of any clinically relevant systemic disease contraindicated for assisted&#xD;
             reproduction or pregnancy&#xD;
&#xD;
          -  history of more than three failed cycles of IVF&#xD;
&#xD;
          -  history of recurrent abortions&#xD;
&#xD;
          -  allergy history for relevant drugs&#xD;
&#xD;
          -  body mass index of &lt;18 or &gt;38 kg/m2 at screening&#xD;
&#xD;
          -  current breastfeeding or pregnancy&#xD;
&#xD;
          -  refusal or inability to comply with the requirements of the protocol for any reason,&#xD;
             including scheduled clinic visits and laboratory tests&#xD;
&#xD;
          -  trophectoderm or blastomere biopsy of the blastocyst(s) to be transferred&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emre Pabuccu, Assoc. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Ufuk University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emre Pabuccu, Assoc. Prof.</last_name>
    <phone>+905324147844</phone>
    <email>emregpabuccu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ufuk University School of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emre Pabuccu, Assoc. Prof.</last_name>
      <email>emregpabuccu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Devine K, Richter KS, Widra EA, McKeeby JL. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018 Feb;109(2):266-275. doi: 10.1016/j.fertnstert.2017.11.004. Epub 2018 Jan 17.</citation>
    <PMID>29338855</PMID>
  </results_reference>
  <results_reference>
    <citation>Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang DZ, Chen ZJ, Kahler E, Pexman-Fieth C, Tournaye H. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018 Dec 1;33(12):2212-2221. doi: 10.1093/humrep/dey306.</citation>
    <PMID>30304457</PMID>
  </results_reference>
  <results_reference>
    <citation>Zarei A, Sohail P, Parsanezhad ME, Alborzi S, Samsami A, Azizi M. Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial. Arch Gynecol Obstet. 2017 Jan;295(1):239-246. doi: 10.1007/s00404-016-4217-4. Epub 2016 Oct 19.</citation>
    <PMID>27761732</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centrum Clinic IVF Center</investigator_affiliation>
    <investigator_full_name>Emre Göksan Pabuçcu</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>progesterone</keyword>
  <keyword>implantation</keyword>
  <keyword>pregnancy</keyword>
  <keyword>abortion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

